The serotonin transporter: a primary target for antidepressant drugs.
about
Subcellular redistribution of the serotonin transporter by secretory carrier membrane protein 2LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptakeFurther structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.Patch Clamp Study of Serotonin-Gated Currents via 5-HT Type 3 Receptors by Using a Novel Approach SHAM for Receptor Channel ScanningDes-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transportersGenetic variation in the proximal promoter of ABC and SLC superfamilies: liver and kidney specific expression and promoter activity predict variationAntidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist4-(4-(dimethylamino)phenyl)-1-methylpyridinium (APP+) is a fluorescent substrate for the human serotonin transporter.Serotonin reuptake transporter deficiency modulates the acute thermoregulatory and locomotor activity response to 3,4-(±)-methylenedioxymethamphetamine, and attenuates depletions in serotonin levels in SERT-KO rats.Three-dimensional structure of the ion-coupled transport protein NhaA.Depression, 5HTTLPR and BDNF Val66Met polymorphisms, and plasma BDNF levels in hemodialysis patients with chronic renal failureConcurrent quantification of tryptophan and its major metabolites.Pharmacogenomics and schizophrenia: clinical implications.Interaction between a serotonin transporter gene promoter region polymorphism and stress predicts depressive symptoms in Chinese adolescents: a multi-wave longitudinal study.Permeation and gating residues in serotonin transporterMass-spectrometric studies of new 6-nitroquipazines-serotonin transporter inhibitorsAntipsychotic drugs influence transport of the beta-adrenergic antagonist [3H]-dihydroalprenolol into neuronal and blood cells.Synthesis, in vitro binding studies and docking of long-chain arylpiperazine nitroquipazine analogues, as potential serotonin transporter inhibitors.Serotonin transporters: implications for antidepressant drug development.Steric hindrance mutagenesis in the conserved extracellular vestibule impedes allosteric binding of antidepressants to the serotonin transporterEffects of Long-Term Treatment with Estradiol and Estrogen Receptor Subtype Agonists on Serotonergic Function in Ovariectomized RatsRepeated administration of imipramine modifies GABAergic transmission in rat frontal cortex.Psychosocial mechanisms of serotonin transporter's genetic polymorphism in susceptibility to major depressive disorder: mediated by trait coping styles and interacted with life events.Serum Serotonin Abnormality in Depression.DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEPComparison of the Antidepressant-Like Effects of Estradiol and That of Selective Serotonin Reuptake Inhibitors in Middle-Aged Ovariectomized Rats.Direct PIP2 binding mediates stable oligomer formation of the serotonin transporter31-year-old female shows marked improvement in depression, agitation, and panic attacks after genetic testing was used to inform treatment.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionRevisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders.Electrophysiological Actions of Synthetic Cathinones on Monoamine Transporters.Comparative modeling of the human monoamine transporters: similarities in substrate binding.Optimization of Molecularly Imprinted Polymers of Serotonin for Biomaterial Applications.Effects of opioids on human serotonin transporters.The long rather than the short allele of 5-HTTLPR predisposes Han Chinese to anxiety and reduced connectivity between prefrontal cortex and amygdalaPalmitate increases the susceptibility of cells to drug-induced toxicity: an in vitro method to identify drugs with potential contraindications in patients with metabolic disease.Jerte Valley cherry-enriched diets improve nocturnal rest and increase 6-sulfatoxymelatonin and total antioxidant capacity in the urine of middle-aged and elderly humans.Evidence of association of serotonin transporter gene polymorphisms with schizophrenia in a South Indian population.Developmental fluoxetine exposure facilitates sexual behavior in female offspring.Functional polymorphism within the promotor of the serotonin transporter gene is associated with severe hyperkinetic disorders.
P2860
Q24298107-5320E6FC-6EEB-4CA6-B7B1-EBD2578A2A22Q24598921-CFD37696-57AE-4909-9B07-9E0F922D70C6Q24603864-9A3EE1F1-FA29-4525-9210-93AD38822470Q24809555-BD7ED4D8-9056-443F-B7E9-35D93D61E004Q28257395-3F51A987-91CB-408F-9CCD-F49951CC4471Q28476093-659711EE-6E54-4DAF-98C5-1018266F6039Q28537732-ECC06D8F-1501-49E2-9DF6-A825F472B256Q30511824-2F101B51-6A8F-418C-91DA-2B5BDAAB533AQ33652473-E719A162-AC1B-4387-8D91-37856D590785Q33886837-AA0F827F-E46D-49D3-8884-36A20A02AD93Q33890188-BDCC8DFA-DA92-4918-8D4E-2EE7C32B17CEQ34118912-5E2BBB73-336B-4231-9351-9DE342A25751Q34575636-09CE04D0-7492-42AF-9AB7-464CB8227344Q34727540-88FCB637-EEAE-4322-8D57-99C9B411A345Q35000759-D49DAF64-1216-481E-98A3-2C8AFA0E1E68Q35645551-FC16169A-1E99-4C73-B984-013DBFA7942DQ35793356-410D9842-5BFF-48E0-93E4-3E20C09DE1EAQ36002440-D3415A38-F484-4710-9C64-65C522E73228Q36341615-82440AC7-4E8C-43F5-A264-4D8FD945F1DEQ36407799-2240CE0B-5215-40C1-A8ED-55F9A8361ADAQ36421526-5D88C093-8E31-442E-84CA-F02AF77CD9A5Q36781548-40C5813E-D179-47FF-8955-98996FDD208EQ36841413-A50F228F-A660-4C5B-8992-97E643FC107BQ37038971-6CE82A41-873B-46D4-9B72-56A99CFDE646Q37201357-D9BEDDFF-02CF-46BE-A48B-D35C3C9E5B03Q37521370-763616DF-D36F-42E4-8665-D8DE262229F4Q37598409-7AFFB1B7-5067-46AE-A6A0-45BA5398E762Q37686841-8FA9B95D-D719-4F5B-8089-610B00648072Q38125568-C338DDF1-9EDC-468B-8927-54BA6FC27C12Q38396133-4EA7137C-D64B-4E42-A03F-FFE66A651E68Q38966221-22C4A697-0CEC-4106-A136-61091F911A90Q39192034-5AD1B0C0-3CD5-4913-BF9D-CE1E84F07E5DQ39862746-DA44AB83-80CF-4912-8322-52CE52A162FDQ40230264-6803B3E5-C111-44B9-87D0-D6241E1A9322Q41452962-2BF4B39B-8D66-4917-9CD3-8027F9056232Q42717461-BD68E436-8191-425C-8344-8F56D9560AAFQ43023769-940032FA-0C9C-4620-A9B1-22ADDA1671A2Q43284473-7312D363-0434-43F7-8154-9F6CACF6B762Q43548532-65A4C0CA-E25B-458F-970B-3019D039648AQ43585236-A67BC0F3-58D0-4580-BA16-8DEDC85EE5EE
P2860
The serotonin transporter: a primary target for antidepressant drugs.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
The serotonin transporter: a primary target for antidepressant drugs.
@en
The serotonin transporter: a primary target for antidepressant drugs.
@nl
type
label
The serotonin transporter: a primary target for antidepressant drugs.
@en
The serotonin transporter: a primary target for antidepressant drugs.
@nl
prefLabel
The serotonin transporter: a primary target for antidepressant drugs.
@en
The serotonin transporter: a primary target for antidepressant drugs.
@nl
P2860
P1476
The serotonin transporter: a primary target for antidepressant drugs.
@en
P2093
D C Williams
P2860
P304
P356
10.1177/026988119801200201
P407
P577
1998-01-01T00:00:00Z